Acquisition Pending
Rallybio acquisition of Avenzo Therapeutics
Announced 1 Jun 2026
Advisers
- Target
- Avenzo Therapeutics
- Acquirer
- Rallybio
- Target based in
- United States
- Buyer based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Passage Bio and Remix Therapeutics merger Jun 2026 · Biotech
- GSK acquisition of Nuvalent Jun 2026 · US$11bn · Biotech
- Treeline Biosciences and Standard BioTools merger Jun 2026 · US$460m · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
Sources
- 1 Jun 2026 Press release (EX-99.1, exhibit), Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology sec.gov
- 1 Jun 2026 Avenzo Therapeutics to be Acquired by Rallybio cooley.com
- 1 Jun 2026 Evercore: Advising Rallybio on its reverse merger with Avenzo Therapeutics evercore.com
